Nectin Therapeutics Series C

Nectin Therapeutics develops immuno-oncology and ADC breakthrough therapies to overcome tumor escape and resistance mechanisms. Their diverse pipeline includes novel immuno-oncology antibodies and ADCs, with an anti-PVR asset currently in Phase 1 clinical trials. They aim to address difficult-to-treat cancers for patients who do not respond to approved immuno-oncology therapies.